Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
LakePharma will manufacture commercial quantities of Akston’s adjuvated COVID-19 vaccine candidate (AKS-452), which is scheduled to begin Phase 1/2 clinical testing later this month.
Lead Product(s): AKS-452
Therapeutic Area: Infections and Infectious Diseases Product Name: AKS-452
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Akston Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 05, 2021